Vaidya Sane Ayurved Laboratories Ltd

Vaidya Sane Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Vaidya Sane Ayurved Laboratories Ltd

₹ 200 3.39%
22 May - close price
madhavbaug.org NSE - SME: MADHAVBAUG
About

Incorporated in 2006, Vaidya Sane Ayurved Laboratories Ltd is the business of running
of hospitals & clinics, and sale of Ayurved based medicines[1]

Key Points

Business Overview[1]
Vaidya Sane Ayurved Laboratories Ltd (Madhavbaug) is among India’s leading chains of cardiac care clinics and hospitals, specializing in non-invasive, Ayurveda-based treatments for chronic conditions like heart disease, diabetes, hypertension, obesity, and joint pain. The company combines traditional medicine with modern diagnostics and technology, supported by in-house manufacturing of Ayurvedic medicines and nutritional products.

Website NSE - SM
  • Market Cap ₹ 210 Cr.
  • Current Price ₹ 200
  • High / Low ₹ 335 / 140
  • Stock P/E 42.6
  • Book Value ₹ 76.5
  • Dividend Yield 0.00 %
  • ROCE 9.57 %
  • ROE 7.04 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company is almost debt free.

Cons

  • Stock is trading at 2.61 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has a low return on equity of 6.55% over last 3 years.
  • Working capital days have increased from 26.8 days to 89.1 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Healthcare Equipment & Supplies Medical Equipment & Supplies

Part of Nifty SME Emerge

Edit Columns
Loading peers table ...

Half Yearly Results

Standalone Figures in Rs. Crores / View Consolidated

Sep 2021 Mar 2022 Sep 2022 Mar 2023 Sep 2023 Mar 2024 Sep 2024 Mar 2025 Sep 2025 Mar 2026
31.36 43.15 45.53 53.50 50.07 47.26 41.02 46.10 47.19 52.44
28.75 38.87 41.09 49.62 48.28 45.88 36.66 39.54 41.07 48.24
Operating Profit 2.61 4.28 4.44 3.88 1.79 1.38 4.36 6.56 6.12 4.20
OPM % 8.32% 9.92% 9.75% 7.25% 3.57% 2.92% 10.63% 14.23% 12.97% 8.01%
0.00 0.34 0.83 0.54 0.47 1.09 0.82 -0.28 0.97 1.22
Interest 0.11 0.09 0.11 0.07 0.16 0.09 0.08 0.78 0.07 0.74
Depreciation 1.17 1.11 1.16 1.44 1.55 1.48 1.77 1.96 2.74 2.88
Profit before tax 1.33 3.42 4.00 2.91 0.55 0.90 3.33 3.54 4.28 1.80
Tax % -2.26% 38.30% 24.75% 25.09% 25.45% 30.00% 29.13% 28.25% 24.77% 5.00%
1.35 2.11 3.01 2.18 0.42 0.63 2.36 2.54 3.22 1.71
EPS in Rs 1.94 2.01 2.86 2.07 0.40 0.60 2.24 2.42 3.06 1.63
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
62.30 74.61 52.01 74.24 99.03 97.33 87.11 99.62
59.20 71.70 47.54 66.92 90.03 94.07 76.98 89.30
Operating Profit 3.10 2.91 4.47 7.32 9.00 3.26 10.13 10.32
OPM % 4.98% 3.90% 8.59% 9.86% 9.09% 3.35% 11.63% 10.36%
0.07 0.07 -1.06 0.34 1.36 1.47 0.57 2.19
Interest 0.70 1.20 0.51 0.63 0.85 0.25 0.10 0.81
Depreciation 1.59 2.23 2.45 2.29 2.60 3.03 3.73 5.61
Profit before tax 0.88 -0.45 0.45 4.74 6.91 1.45 6.87 6.09
Tax % 44.32% 24.44% 15.56% 27.00% 24.89% 28.28% 28.68% 18.88%
0.50 -0.56 0.39 3.47 5.19 1.05 4.90 4.93
EPS in Rs 111.11 -124.44 86.67 3.30 4.94 1.00 4.66 4.69
Dividend Payout % 0.00% 0.00% 0.00% 0.00% 5.06% 0.00% 0.00% 0.00%
Compounded Sales Growth
10 Years: %
5 Years: 14%
3 Years: 0%
TTM: 14%
Compounded Profit Growth
10 Years: %
5 Years: 40%
3 Years: -2%
TTM: -14%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: -7%
1 Year: 39%
Return on Equity
10 Years: %
5 Years: 9%
3 Years: 7%
Last Year: 7%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 0.05 0.05 0.05 10.51 10.51 10.51 10.51 10.51
Reserves 8.74 8.17 9.72 25.37 30.30 44.51 49.19 69.88
8.67 5.97 1.02 1.06 0.13 1.68 1.46 2.59
11.41 14.93 15.02 13.07 14.34 14.03 12.67 14.02
Total Liabilities 28.87 29.12 25.81 50.01 55.28 70.73 73.83 97.00
15.66 15.51 17.16 17.01 20.95 22.08 26.97 28.69
CWIP 2.02 3.79 0.38 1.23 1.67 2.60 1.26 1.40
Investments 0.02 0.02 0.01 21.49 14.85 24.88 26.38 43.21
11.17 9.80 8.26 10.28 17.81 21.17 19.22 23.70
Total Assets 28.87 29.12 25.81 50.01 55.28 70.73 73.83 97.00

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
1.58 7.72 5.77 -13.31 -0.43 3.39 7.58 4.17
-10.05 -3.93 -0.67 -7.52 1.00 -17.42 -6.91 -22.08
7.71 -3.63 -5.26 22.49 -1.38 14.46 -0.54 16.73
Net Cash Flow -0.77 0.16 -0.16 1.66 -0.81 0.43 0.14 -1.17
Free Cash Flow -7.39 3.87 5.08 -16.30 -7.41 -1.70 0.31 -3.30
CFO/OP 65% 272% 143% -166% 24% 129% 85% 61%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 21.38 12.23 18.53 17.50 23.81 21.90 29.46 34.88
Inventory Days 76.92 49.49 35.00 39.92 31.08 19.42
Days Payable 137.65 138.39 146.74 113.10 111.56 96.97
Cash Conversion Cycle -39.34 -76.67 -93.21 17.50 23.81 -51.28 -51.02 -42.67
Working Capital Days -57.94 -55.28 -53.55 -30.48 1.51 -5.25 -3.52 89.14
ROCE % 4.74% 16.97% 22.50% 19.93% 3.07% 13.86% 9.57%

Insights

In beta
Dec 2006 Dec 2013 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
EBITDA Margin
%

Log in to view insights

Please log in to see hidden values.

Login
Number of Clinics (Total Network)
Number
Average Revenue per Clinic (Enterprise)
INR Lacs
Number of Hospitals
Number
Total Patient Footfall
Number
New Patient Footfall
Number
Research Papers Published
Number

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

1 Recently
Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Sep 2024Mar 2025Sep 2025Dec 2025Mar 2026
66.34% 66.34% 66.34% 66.34% 66.34% 66.34% 66.34% 66.34% 66.34% 66.34% 66.34% 66.34%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.21% 0.00% 0.00%
33.66% 33.68% 33.67% 33.67% 33.66% 33.66% 33.66% 33.66% 33.66% 33.45% 33.66% 33.66%
No. of Shareholders 464534595637731846881821787712700671

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Concalls